antihemophilic factorhttp://www.unboundmedicine.com/medline/ebm/research/antihemophilic_factorUnbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.en-usUnbound Medicine, Inc.Alterations in cochlear function during induced acute hyperinsulinemia in an animal model.http://www.unboundmedicine.com/medline/ebm/record/19893948/full_citation/Alterations_in_cochlear_function_during_induced_acute_hyperinsulinemia_in_an_animal_model_Angeli RD, Lavinsky L, Dolganov A 
Alterations in cochlear function during induced acute hyperinsulinemia in an animal model. [Journal Article]
Braz J Otorhinolaryngol 2009 Sep-Oct; 75(5):760-4.
Abstract | Full CitationA case of epithelioid hemangioendothelioma of the liver: detection by FDG-PET.http://www.unboundmedicine.com/medline/ebm/record/19893296/full_citation/A_case_of_epithelioid_hemangioendothelioma_of_the_liver:_detection_by_FDG_PET_Katsushima S, Komeda T, Endoh B, et al. 
A case of epithelioid hemangioendothelioma of the liver: detection by FDG-PET. [Journal Article]
Nippon Shokakibyo Gakkai Zasshi 2009 Nov; 106(11):1650-9.
Abstract | Full Citation | Find Related Articles Induction of heme oxygenase-1 in factor VIII-deficient mice reduces the immune response to therapeutic factor VIII.http://www.unboundmedicine.com/medline/ebm/record/19890094/full_citation/Induction_of_heme_oxygenase_1_in_factor_VIII_deficient_mice_reduces_the_immune_response_to_therapeutic_factor_VIII_Dimitrov JD, Dasgupta S, Navarrete AM, et al. 
Induction of heme oxygenase-1 in factor VIII-deficient mice reduces the immune response to therapeutic factor VIII. [JOURNAL ARTICLE]
Blood 2009 Nov 4.
Abstract | Full Citation | Publisher Full Text | Find Related Articles Short-term ethinylestradiol treatment suppresses inferior caval vein thrombosis in obese mice.http://www.unboundmedicine.com/medline/ebm/record/19888539/full_citation/Short_term_ethinylestradiol_treatment_suppresses_inferior_caval_vein_thrombosis_in_obese_mice_Cleuren AC, van Hoef B, Hoylaerts MF, et al. 
Short-term ethinylestradiol treatment suppresses inferior caval vein thrombosis in obese mice. [Journal Article]
Thromb Haemost 2009 Nov; 102(5):993-1000.
Abstract | Full Citation | Find Related Articles Effects of tissue factor, thrombomodulin and elevated clotting factor levels on thrombin generation in the calibrated automated thrombogram.http://www.unboundmedicine.com/medline/ebm/record/19888532/full_citation/Effects_of_tissue_factor_thrombomodulin_and_elevated_clotting_factor_levels_on_thrombin_generation_in_the_calibrated_automated_thrombogram_Machlus KR, Colby EA, Wu JR, et al. 
Effects of tissue factor, thrombomodulin and elevated clotting factor levels on thrombin generation in the calibrated automated thrombogram. [Journal Article]
Thromb Haemost 2009 Nov; 102(5):936-44.
Abstract | Full Citation | Find Related Articles Factor VIII-eGFP fusion proteins with preserved functional activity for the analysis of the early secretory pathway of factor VIII.http://www.unboundmedicine.com/medline/ebm/record/19888531/full_citation/Factor_VIII_eGFP_fusion_proteins_with_preserved_functional_activity_for_the_analysis_of_the_early_secretory_pathway_of_factor_VIII_Heinz S, Schüttrumpf J, Simpson JC, et al. 
Factor VIII-eGFP fusion proteins with preserved functional activity for the analysis of the early secretory pathway of factor VIII. [Journal Article]
Thromb Haemost 2009 Nov; 102(5):925-35.
Abstract | Full Citation | Find Related Articles Development of freeze-dried biosynthetic Factor VIII: I. A case study in the optimization of formulation.http://www.unboundmedicine.com/medline/ebm/record/19883259/full_citation/Development_of_freeze_dried_biosynthetic_Factor_VIII:_I__A_case_study_in_the_optimization_of_formulation_Jameel F, Tchessalov S, Bjornson E, et al. 
Development of freeze-dried biosynthetic Factor VIII: I. A case study in the optimization of formulation. [JOURNAL ARTICLE]
Pharm Dev Technol 2009 Dec; 14(6):687-697.
Abstract | Full Citation | Find Related Articles Evolution of recombinant factor VIII safety: KOGENATE((R)) and Kogenate ((R)) FS/Bayer.http://www.unboundmedicine.com/medline/ebm/record/19882376/full_citation/Evolution_of_recombinant_factor_VIII_safety:_KOGENATE__R___and_Kogenate___R___FS/Bayer_Lusher JM, Scharrer I 
Evolution of recombinant factor VIII safety: KOGENATE((R)) and Kogenate ((R)) FS/Bayer. [JOURNAL ARTICLE]
Int J Hematol 2009 Nov 3.
Abstract | Full Citation[Kidney transplantation in patient with haemophilia A.]http://www.unboundmedicine.com/medline/ebm/record/19879788/full_citation/[Kidney_transplantation_in_patient_with_haemophilia_A_]El Bakkouri J, Mamdouh A, Faez S, et al. 
[Kidney transplantation in patient with haemophilia A.] [JOURNAL ARTICLE]
Transfus Clin Biol 2009 Oct 29.
Abstract | Full Citation | Find Related Articles Postmarketing surveillance study of KOGENATE((R)) Bayer with Bio-Set((R)) in patients with haemophilia A: evaluation of patients' satisfaction after switch to the new reconstitution system.http://www.unboundmedicine.com/medline/ebm/record/19878338/full_citation/Postmarketing_surveillance_study_of_KOGENATE__R___Bayer_with_Bio_Set__R___in_patients_with_haemophilia_A:_evaluation_of_patients'_satisfaction_after_switch_to_the_new_reconstitution_system_Vidovic N, Musso R, Klamroth R, et al. 
Postmarketing surveillance study of KOGENATE((R)) Bayer with Bio-Set((R)) in patients with haemophilia A: evaluation of patients' satisfaction after switch to the new reconstitution system. [JOURNAL ARTICLE]
Haemophilia 2009 Oct 29.
Abstract | Full Citation